[Featured Stock] JW Jungwoo Pharmaceutical Shows Strength as Roche's 'Actemra' Used to Verify COVID-19 Phase 3 Clinical Treatment Effectiveness

[Asia Economy Reporter Yoo Hyun-seok] JW Pharmaceutical is showing strong performance. It appears that the news of Roche planning to conduct a Phase 3 clinical trial combining the arthritis treatment drug 'Actemra' and Gilead's new drug candidate 'Remdesivir' to verify the treatment effect for the novel coronavirus infection (COVID-19) has influenced this trend.

As of 9:55 AM on the 29th, JW Pharmaceutical was trading at 35,100 KRW, up 5.09% (1,700 KRW) compared to the previous trading day.

According to related industries, Roche conducted a global Phase 3 clinical trial in March to confirm the COVID-19 treatment effect of Actemra. Additionally, a Phase 3 clinical trial combining Remdesivir is also underway. Patient enrollment for this trial will begin next month.

Actemra is an autoimmune disease treatment used for rheumatoid arthritis. Actemra is a drug for which JW Pharmaceutical holds the development and commercialization rights. Recently, it has been highlighted as a treatment for COVID-19.